Medline Inc. Class A Common Stock (MDLN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Medline Inc. Class A Common Stock stock (MDLN) is currently trading at $42.03. Medline Inc. Class A Common Stock PE ratio is 29.88. Medline Inc. Class A Common Stock PS ratio (Price-to-Sales) is 1.22. Analyst consensus price target for MDLN is $53.37. WallStSmart rates MDLN as Underperform.
- MDLN PE ratio analysis and historical PE chart
- MDLN PS ratio (Price-to-Sales) history and trend
- MDLN intrinsic value — DCF, Graham Number, EPV models
- MDLN stock price prediction 2025 2026 2027 2028 2029 2030
- MDLN fair value vs current price
- MDLN insider transactions and insider buying
- Is MDLN undervalued or overvalued?
- Medline Inc. Class A Common Stock financial analysis — revenue, earnings, cash flow
- MDLN Piotroski F-Score and Altman Z-Score
- MDLN analyst price target and Smart Rating
Medline Inc.
📊 No data available
Try selecting a different time range
MDLN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Medline Inc. Class A Common Stock (MDLN)
MDLN trades at a significant discount to its Graham intrinsic value of $66.92, offering a 33% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Medline Inc. Class A Common Stock (MDLN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, price/sales, eps growth. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Medline Inc. Class A Common Stock (MDLN) Key Strengths (4)
Earnings per share surging 1255.00% year-over-year
100.39% of shares held by major funds and institutions
Large-cap company with substantial market presence
Paying $1.22 for every $1 of annual revenue
Supporting Valuation Data
Medline Inc. Class A Common Stock (MDLN) Areas to Watch (5)
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Low profitability relative to shareholder equity
Premium pricing at 3.2x book value
Solid revenue growth at 14.80% per year
Supporting Valuation Data
Medline Inc. Class A Common Stock (MDLN) Detailed Analysis Report
Overall Assessment
This company scores 52/100 in our Smart Analysis, earning a C- grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Market Cap. Valuation metrics including Price/Sales (1.22) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 1255.00%.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Return on Equity. Some valuation metrics including Price/Book (3.23) suggest expensive pricing. Growth concerns include Revenue Growth at 14.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 6.53%, Operating Margin at 5.69%, Profit Margin at 4.08%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 6.53% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 14.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Institutional Own.) and negatives (Operating Margin, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MDLN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MDLN's Price-to-Sales ratio of 1.22x sits near its historical average of 1.24x (33th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 1.36x set in Mar 2026, and 3% above its historical low of 1.18x in Mar 2026.
Compare MDLN with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Medline Inc. Class A Common Stock (MDLN) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Medline Inc. Class A Common Stock is a mature, profitable business with steady cash generation. Revenue reached 28.4B with 15% growth year-over-year. Profit margins are strong at 408.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 653.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -113M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Debt management: total debt of 16.6B is significantly higher than cash (955M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Medline Inc. Class A Common Stock.
Bottom Line
Medline Inc. Class A Common Stock is a well-established business delivering consistent profitability with 408.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Medline Inc. Class A Common Stock(MDLN)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.